Compare Abeona Therapeutics Inc (ABEO) vs ASE Technology Holding Co Ltd (ASX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ASE Technology Holding Co Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while ASE Technology Holding Co Ltd trades at $40.3 (market cap $89.31B). The key difference: ASE Technology Holding Co Ltd is far larger — about 239.2× Abeona Therapeutics Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ASX | |
|---|---|---|
Market Cap | $373.32M | $89.31B |
Sector | Health | Technology |
52-Week High | $7.23 | $45.12 |
52-Week Low | $4.17 | $9.50 |
Enterprise Value | $228.22M | $93.75B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ASE Technology Holding (ASX) trades at $39.65, down 5.3% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong quarterly earnings beats, with Q1 2026 EPS of $0.20 beating expectations of $0.1703. Revenue grew to $645.39B in 2025, with net income of $40.02B, while valuation ratios like P/E of 67.98 and P/B of 8.67 suggest premium pricing. Recent news highlights AI-driven demand boosting its LEAP advanced packaging business, with 2026 revenue projected above $3.5B.
Outlook remains positive due to AI infrastructure growth and margin expansion, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is 80% buy, with institutional sentiment buoyed by earnings momentum, though the stock's recent decline may reflect profit-taking after a 77.1% three-month surge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →
